Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of pharmaceutical products to help in the treatment of central nervous system disorders, now has a product portfolio made up of HETLIOZ® (tasimelteon), Fanapt® (iloperidone), Tradipitant (VLY-686), Trichostatin A, and AQW051, all of which address high unmet medical needs and improve the lives of patients.
The company recently released its financial results for the third quarter of 2016 (ended September 30) highlighting that total revenues grew to $38.5 million, an increase of 7% over the second quarter of this year. This was also a 36% increase compared to Vanda’s $28.3 million during the third quarter of 2015, with an increase to cash of $6.6 million.
As a result, several research firms across the U.S. have commented on VNDA. Aegis Capital Corp. (http://dtn.fm/G6slI) initiated coverage of Vanda Pharmaceuticals, giving the company a ‘Buy’ rating with a target price of $24. The report’s investment highlights included HETLIOZ® for non-24, Fanapt®’s asset life extension through November 2027 due to the company’s ‘610 patent win, and the fact that Vanda R&D programs in the pipeline carry lower than average development risks.
Jefferies Group, Brean Capital, and Piper Jaffray Cos. also gave Vanda Pharmaceuticals a ‘Buy’ rating, with a target price ranging between $19 and $24. JMP Securities gave Vanda a “Market Outperform” rating, upping its price target on shares from $18 to $22. In addition, many large investors have also upgraded their positions with Vanda Pharmaceuticals, Inc.
According to the Cerbat Gem Market News and Analysis (http://dtn.fm/bQS1s) site, the Bank of Montreal in Canada bought a new stake in shares worth approximately $132,000; UBS Asset Management Americas, Inc. increased its position within the company by just under 11%, making them the proud owners of 16,300 shares; and Paloma Partners Management Co. bought a new position worth approximately $192,000. Jane Street Group LLC and TFS Capital LLC bought new positions worth about $200,000 and $210,000 respectively.
Vanda Pharmaceuticals, Inc.’s earnings per share beat the consensus estimate by $0.13, and it beat the earning consensus estimate by approximately $0.43 million. The company’s non-GAAP EPS came in above street estimates of $0.01 at a huge $0.11, and full year revenue has gone from $143 million to $153 million.
For more information, visit the company’s website at www.vandapharmaceuticals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
